Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (GEM-1801)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Responsible person designated by the sponsor
- Phone Number: +34 93 434 44 12
- Email: investigacion@mfar.net
Study Contact Backup
- Name: A responsible person Designated by the sponsor
- Phone Number: +34 93 434 44 12
- Email: investigacion@mfar.net
Study Locations
-
-
-
Madrid, Spain
- Hospital General Universitario Gregorio Marañón
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Pamplona, Spain
- Clinica Universidad de Navarra
-
-
Alicante
-
Alcoy, Alicante, Spain, 03804
- Hospital Virgen de los Lirios
-
-
Andalusia
-
Granada, Andalusia, Spain
- Hospital Universitario Virgen de las Nieves
-
Granada, Andalusia, Spain
- Onconogranada
-
Málaga, Andalusia, Spain
- Hospital Universitario Regional de Málaga
-
-
Barcelona
-
Barcelona, Barcelona, Spain, 08035
- Hospital Universitari Vall d'Hebron
-
Sabadell, Barcelona, Spain
- Parc Taulí
-
-
Basque Country
-
Vitoria-Gasteiz, Basque Country, Spain
- Hospital Universitario Araba Txagorritxu Victoria
-
-
Cantabria
-
Santander, Cantabria, Spain
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Burgos, Castille and León, Spain
- Hospital Universitario de Burgos
-
Salamanca, Castille and León, Spain
- Complejo Asistencial Universitario de Salamanca
-
Valladolid, Castille and León, Spain
- Hospital Universitario Río Hortega
-
-
Castille-La Mancha
-
Ciudad Real, Castille-La Mancha, Spain
- Hospital General de Ciudad Real
-
-
Catalonia
-
Badalona, Catalonia, Spain
- Instituto Catalán de Oncología Badalona
-
Barcelona, Catalonia, Spain
- Hospital de la Santa Creu y Sant Pau
-
Barcelona, Catalonia, Spain
- Hospital Universitario Quirón Dexeus
-
-
Extremadura
-
Cáceres, Extremadura, Spain
- Hospital Universitario San Pedro Alcántara
-
-
Guipuzcoa
-
Donostia / San Sebastian, Guipuzcoa, Spain, 20014
- Onkologikoa
-
-
La Rioja
-
Logroño, La Rioja, Spain, 26006
- Hospital San Pedro
-
-
Lugo
-
Lugo, Lugo, Spain, 27003
- Hospital Lucus Augusti
-
-
Madrid
-
Madrid, Madrid, Spain
- Hospital Universitario Ramon y Cajal
-
Madrid, Madrid, Spain
- Hospital Universitario La Paz
-
Madrid, Madrid, Spain, 28006
- Hospital Universitario La Princesa
-
Majadahonda, Madrid, Spain
- Hospital Universitario Puerta de Hierro-Majadahonda
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Marbella, Málaga, Spain
- Hospital Costa del Sol
-
-
Navarre
-
Pamplona, Navarre, Spain
- Complejo Hospitalario de Navarra
-
-
Palma
-
Palma de Mallorca, Palma, Spain, 07198
- Hospital Universitario Son Llàtzer
-
-
Pontevedra
-
Pontevedra, Pontevedra, Spain, 36164
- Complejo Hospitalario de Pontevedra
-
-
Sevilla
-
Seville, Sevilla, Spain
- Hospital Universitario de Valme
-
-
Toledo
-
Toledo, Toledo, Spain, 45004
- Hospital Virgen de la Salud
-
-
Valencia
-
Alzira, Valencia, Spain, 46600
- Hospital La Ribera
-
Valencia, Valencia, Spain
- Hospital General Universitario de Valencia
-
Valencia, Valencia, Spain
- Instituto Valenciano de Oncología
-
-
Valladolid
-
Valladolid, Valladolid, Spain, 47003
- Hospital Clínico Universitario de Valladolid
-
-
Zaragoza
-
Zaragoza, Zaragoza, Spain, 50009
- Hospital Clínico Universitario Lozano Blesa
-
Zaragoza, Zaragoza, Spain, 500009
- Hospital Universitario Miguel Servet
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as: a. Disease onset as metastatic or unresectable disease; b. First metastatic or unresectable relapse in the pre-established dates (after January 8, 2018) in a patient with previous localised melanoma and completely resected on dates before the pre-inclusion period.
- Signing the Informed Consent Form (ICF).
- A patient may have received the first or subsequent treatments for metastatic or unresectable disease in a hospital other than the centre where the ICF was signed, as long as the patient meets the inclusion criteria 1.
- A patient can only sign one ICF (cannot sign an ICF in two different centres).
- If a patient signs the ICF in a centre during the first-line therapy and then goes to another centre with consideration for the following lines: If the centre is associated with the GEM-1801 study, researchers will do their best to update the following lines and the patient status, introducing the new information in the centre where the ICF was initially signed. This information will be provided by the patient before contacting the principal investigator and always with prior consent of the patient, who will have previously provided the consent to contact by telephone for this purpose. If this second (or subsequent) centre is not associated with the GEM- 1801 study, this will be considered loss of follow-up, unless the patient returns to the GEM-1801 start centre, wherein the reporting physicians will do their best to update the information from other centres, always with prior patient consent, who will have previously signed the ICF; c) A patient card with the assigned code will be delivered.
Exclusion Criteria:
- Any patient not complying with inclusion criteria.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Advanced Melanoma
Patients of legal age with stage III, metastatic, or unresectable melanoma at first diagnosis after January 8, 2018. First diagnosis is understood as:
|
The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study.
No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sample Characteristics
Time Frame: Baseline
|
Sociodemographic and disease characteristics of patients diagnosed with stage III, metastatic or unresectable melanoma at first diagnosis.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Iván Márquez Rodas, M.D., Hospital General Universitario Gregorio Marañón
- Principal Investigator: Salvador Martín Algarra, M.D., Clinica Universidad de Navarra, Universidad de Navarra
Publications and helpful links
General Publications
- Cerezuela-Fuentes P, Pinero-Madrona A, Munoz-Couselo E, Manzano JL, Berciano-Guerrero MA, Majem M, Espinosa E, Soria A, Ayala de Miguel P, Garcia Castano A, Crespo G, Gutierrez Sanz L, Aguado de la Rosa C, Fernandez-Morales LA, Puertolas T, Fra Rodriguez J, Rodriguez de la Borbolla M, Bellido L, Lopez Castro R, Navarro Perez V, Garcia Arroyo FR, Villa Guzman JC, Campos Balea B, Hernandez B, Martin Algarra S, Marquez-Rodas I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clin Transl Oncol. 2026 Jun;28(6):2377-2385. doi: 10.1007/s12094-025-04164-w. Epub 2025 Dec 20.
- Espinosa E, Berciano-Guerrero MA, Munoz-Couselo E, Puertolas T, Manzano JL, Soria A, de Miguel PA, Crespo G, Sanz LG, Cerezuela-Fuentes P, de la Rosa CA, Majem M, Castano AG, Berrocal A, Arroyo FRG, de la Borbolla MR, Bellido L, Martinez JM, Fernandez LA, Carnicero AM, Castro RL, Rodriguez AB, Lecumberri MJ, Guzman JCV, Balea BC, Rodriguez JF, Bautista JV, Perez VN, Mujika K, Subias MC, Hernandez B, Algarra SM, Marquez-Rodas I. Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801. Clin Transl Oncol. 2026 May;28(5):1807-1814. doi: 10.1007/s12094-025-04098-3. Epub 2025 Nov 28.
- Ayala-de Miguel P, Munoz-Couselo E, Gutierrez-Sanz L, Fernandez LA, Navarro-Perez V, Berciano-Guerrero MA, Garcia-Arroyo F, Aguado-de la Rosa C, Cerezuela-Fuentes P, Majem M, Campos-Balea B, Soria A, Hernandez-Marin B, Garcia-Castano A, Martin-Algarra S, Marquez-Rodas I. Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801). Clin Transl Oncol. 2026 Jan;28(1):320-329. doi: 10.1007/s12094-025-04005-w. Epub 2025 Jul 27.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GEM-1801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.